Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Financing Activities: 2011-2025

Historic Cash from Financing Activities for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to -$26.6 million.

  • Enanta Pharmaceuticals' Cash from Financing Activities fell 15.33% to -$8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.6 million, marking a year-over-year increase of 3.65%. This contributed to the annual value of -$26.6 million for FY2025, which is 3.65% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Cash from Financing Activities stood at -$26.6 million for FY2025, which was up 3.65% from -$27.6 million recorded in FY2024.
  • Enanta Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $198.1 million during FY2023, with a 5-year trough of -$27.6 million in FY2024.
  • Its 3-year average for Cash from Financing Activities is $48.0 million, with a median of -$26.6 million in 2025.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Cash from Financing Activities skyrocketed by 889.00% in 2023, and later slumped by 113.94% in 2024.
  • Enanta Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $3.1 million in 2021, then soared by 550.42% to $20.0 million in 2022, then spiked by 889.00% to $198.1 million in 2023, then plummeted by 113.94% to -$27.6 million in 2024, then increased by 3.65% to -$26.6 million in 2025.